Williams, a 23-time Grand Slam champion, explained that the decision to use a GLP-1 agonist came after she struggled to return to her optimal health following the births of her two daughters. Despite trying various approaches, including extensive exercise and different diets such as vegan and vegetarian, she was unable to achieve her desired weight and health levels. “As an athlete and as someone that has done everything, I just couldn’t get my weight to where I needed to be at a healthy place — and believe me, I don’t take shortcuts,” Williams said.
She noted that, after beginning the medication about a year ago, her overall health improved significantly. Doctors told her that her blood sugar levels are now better, and she feels less strain on her joints, particularly her knees, which had troubled her after pregnancy. Williams also highlighted that she did not experience any side effects from the medication, despite being aware of their potential.
Addressing the stigma surrounding weight loss medications, Williams emphasized the importance of normalizing their use, especially given the higher risk of diabetes in African American communities—a concern that influenced her decision. Through her partnership with healthcare company Ro, Williams hopes to encourage more open discussions about medical support for weight management.
Williams continues to stay active in various business ventures and remains a prominent figure in both sports and health advocacy. For ongoing updates about her career and personal projects, fans can follow Serena’s official website or check out her latest posts on Twitter.